Molecular and cellular effects of azilsartan: A new generation angiotensin II receptor blocker

Journal of Hypertension

Volumn 29, Issue 12, 2011, Pages 2476-2483

  Kajiya, Takashi ^a,b   Ho, Christopher ^b   Wang, Jiaming ^b   Vilardi, Ryan ^b   Kurtz, Theodore W ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin II type 1 receptor blockers; angiotensins; azilsartan; azilsartan medoxomil; hypertension; TAK 491; TAK 536; valsartan

Indexed keywords

ADIPONECTIN; ADIPSIN; ANGIOTENSIN 1 RECEPTOR; AZILSARTAN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD36 ANTIGEN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VALSARTAN;

ADIPOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD PRESSURE; CELL ASSAY; CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; INCUBATION TIME; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROADIPOCYTE; SMOOTH MUSCLE FIBER;

EID: 81355160382     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834c46fd     Document Type: Article

References (23)

1. Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009; 32:826-834.
2. Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J. Clin Hypertens (Greenwich) 2011; 13:81-88.
3. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57:413-420.
4. Mancia G, Parati G. Guiding antihypertensive treatment decisions using ambulatory blood pressure monitoring. Curr Hypertens Rep 2006; 8:330-337.
5. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension 2010; 56:765-773.
6. White WB. Relating cardiovascular risk to out-of-office blood pressure and the importance of controlling blood pressure 24 h a day. Am. J. Med 2008; 121:S2-S7.
7. Takeda Pharmaceuticals North America. Edarbi prescribing information. http://www.edarbi.com/. [Accessed 6 July 2011]
8. Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J. Pharmacol Exp Ther 2011; 336:801-808.
9. Kurtz TW, Pravenec M. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system. Am. J. Hypertens 2008; 21:852-859.
10. Benson SC, Iguchi R, Ho CI, Yamamoto K, Kurtz TW. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: Are all molecules the same? J. Hypertens 2008; 26:973-980.
11. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR{gamma}-modulating activity. Hypertension 2004; 43:993-1002.
12. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptorgamma activity. Circulation 2004; 109:2054-2057.
13. Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Bohm C, et al. Liver-specific PPAR{alpha}-target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008; 57:1405-1413.
14. He H, Yang D, Ma L, Luo Z,Ma S, Feng X, et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. Hypertension 2010; 55:869-879.
15. Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am. J. Hypertens 2007; 20:579-586.
16. Ramirez-Zacarias JL, Castro-Munozledo F, Kuri-Harcuch W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 1992; 97:493-497.
17. Martin MM, Willardson BM, Burton GF, White CR, McLaughlin JN, Bray SM, et al. Human angiotensin II type 1 receptor isoforms encoded by messenger RNA splice variants are functionally distinct. Mol Endocrinol 2001; 15:281-293.
18. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30:e36.
19. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 2001; 22:153-183.
20. Buclin T, Biollaz J, Kung S, Appenzeller M, Nussberger J, Higgins T, et al. Tolerability, pharmacokinetics, and pharmacodynamics of the angiotensin II antagonist TAK-536 in healthy volunteers. Clin Pharmacol Ther 1995; 57:204.
21. Takeda Pharmaceuticals North America. Azilsartan medoxomil clinical pharmacology and biopharmaceutics review. New drug application to the Food and Drug Administration 2010; NDA 200796: 1-26. http:// www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/ 200796Orig1s000ClinPharmR.pdf. [Accessed 14 July 2011]
22. Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J. Biol Chem 2006; 281:19288-19295.
23. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Laznik D, et al. Antidiabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010; 466:451-456.